A Growing Crisis Among the Young

Colorectal cancer rates among adults under 50 have been climbing by nearly 3 percent annually , and for years, doctors could see the numbers rising without fully understanding why. Now, a landmark Boston study is offering the clearest biological picture yet of what makes colon cancer in younger patients distinct — and potentially more dangerous.

Researchers at Mass General Brigham, Dana-Farber Cancer Institute, and the Broad Institute published a study examining why younger patients are increasingly being diagnosed with the disease. Experts say the study — the largest of its kind — will be a critical resource for cancer researchers. The findings were published in the journal Nature Medicine.

What Scientists Found Inside the Tumors

To understand these shifts, researchers analyzed 189 tumors and more than 850,000 individual cell nuclei, including samples from 54 patients under 50. Using a technique called single-nucleus RNA sequencing, the researchers measured gene activity in more than 850,000 individual cells. The sheer scale of the dataset sets this study apart from anything that has come before it.

Researchers observed that tumors in younger patients appeared to have a different composition of cells — namely, a much higher proportion of connective and supporting cells, known as stromal cells. Studies of other types of solid cancer have linked stromal cells to chemotherapy resistance. According to the researchers, those stromal cells can produce factors that suppress the immune system, making it harder for the body to fight cancer. Moreover, they may act as a barrier that hinders drug delivery into tumors.

Younger patients’ cancer cells also showed higher activity of long non-coding RNAs, many with unknown functions, along with gene activity suggesting stronger cell signaling that could help cancer cells invade nearby tissue. In addition, scientists found evidence suggesting that younger patients experience stronger intercellular signaling — a characteristic that may help explain why the disease can behave more aggressively in this age group.

Real Hope, With Measured Caution

The findings offer hope to survivors like Kristen Vincent of Orleans, who was just 37 years old when she learned she had stage 3 colorectal cancer. Her story reflects a troubling pattern that has left both patients and doctors searching for answers. For many young adults, a colorectal cancer diagnosis arrives as a shock — they are often outside the age range traditionally associated with the disease, and screening guidelines have historically not prioritized them.

While the researchers view their work as providing essential insights into the nature of tumors in younger individuals, they caution that these findings do not yet establish a clear causal link between the observed differences and the more aggressive disease behavior. The findings also do not yet explain why more young people are developing colorectal cancer in the first place. That question remains open — and urgent.

A New Road Map for Treatment

“Before we were just trying to look for differences, now we have some differences that we can kind of dig into further to hopefully understand biology, and that could lead to interventions down the road,” the researchers said. That shift — from searching blindly to following specific biological leads — is significant. It means future research can be targeted rather than exploratory.

The study also found differences in how genes are expressed in the tumors of younger people — a finding that experts say could lead to new therapeutic targets. With a dataset this large and this focused, scientists now have a foundation to develop treatments tailored specifically to younger patients rather than applying a one-size-fits-all approach. As colorectal cancer continues its troubling rise among people in their 20s, 30s, and 40s, studies like this one are no longer a luxury — they are a necessity.